Vinay M Girijavallabhan

This inventor holds 23 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Nucleoside Derivatives. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Southern Research Institute. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vinay M Girijavallabhan. Retrieved from https://idiyas.com/inventor/vinay-m-girijavallabhan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 2)

% Patents Active = 87.0

CIPO Patents = 2

EPO Patents = 11 (Patent Applications = 8)

Average Co-Inventor Count = 8.2

ph-index = 9

Forward Citations = 283(Granted Patents)

Location History:

Woburn, MA (US) (2010)
Watertown, MA (US) (2009 - 2011)
Denville, NJ (US) (2010 - 2017)
Whippany, NJ (US) (2015 - 2021)

Company Filing History:

13 out of 2,405

Merck Sharp + Dohme Corp.

Southern Research Institute

patents

4. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Nucleoside Derivatives

Reverse Transcriptase Inhibitors

Viral Diseases

Inflammatory Disorders

Cyclic Phosphonate

Substituted Pyridine

Substituted Pyrimidine

Alkynyl Substituents

Cyano Substituents

Azido Substituents

Disubstituted Derivatives

Therapeutic Compounds

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10953029 - 4'-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof (2021-03-23),

2. 9777035 - 4'-substituted nucleoside reverse transcriptase inhibitors (2017-10-03),

3. 9765107 - Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2017-09-19),

4. 9732111 - 2'-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2017-08-15),

5. 9457039 - 2'-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2016-10-04),

6. 9433621 - Substituted pyridine and pyrimidine derivatives and their use in treating viral infections (2016-09-06),

7. 9416154 - 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2016-08-16),

8. 9242988 - 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2016-01-26),

9. 9156872 - 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2015-10-13),

10. 9150603 - 2'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases (2015-10-06),

11. 9061041 - 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2015-06-23),

12. 8697694 - Substituted pyridine and pyrimidine derivatives and their use in treating viral infections (2014-04-15),

13. 8569336 - Compounds for the treatment of inflammatory disorders (2013-10-29),

14. 8541572 - Compounds for the treatment of inflammatory disorders (2013-09-24),

15. 8178553 - Compounds for the treatment of inflammatory disorders (2012-05-15),

Title: Innovator Spotlight: Vinay M Girijavallabhan - Pioneering 4'-Substituted Nucleoside Reverse Transcriptase Inhibitors

Introduction: Meet Vinay M Girijavallabhan, a visionary inventor based in Whippany, NJ, with an impressive portfolio of 23 patents. His groundbreaking work in the field of 4'-substituted nucleoside derivatives has significantly advanced the fight against HIV and AIDS.

Latest Patents: Vinay's latest patents revolve around 4'-substituted nucleoside reverse transcriptase inhibitors, specifically focusing on their formula and applications in combating HIV. These innovations not only inhibit HIV reverse transcriptase but also play a crucial role in the prophylaxis and treatment of HIV infections, as well as in delaying the onset and progression of AIDS and/or ARC.

Career Highlights: Throughout his career, Vinay has made significant contributions to the pharmaceutical industry. He has held key roles at renowned companies such as Merck Sharp & Dohme Corporation and Schering Corporation, where his expertise and innovative mindset have driven groundbreaking research and development initiatives.

Collaborations: Vinay has collaborated closely with esteemed professionals in the field, including Joseph A Kozlowski and Brian J Lavey. Together, they have worked on cutting-edge projects that have reshaped the landscape of antiretroviral therapy and HIV treatment strategies.

Conclusion: In conclusion, Vinay M Girijavallabhan stands as a beacon of innovation in the realm of antiviral medications. His relentless pursuit of scientific excellence and commitment to improving global health outcomes underscore his status as a pioneering inventor in the fight against HIV and AIDS.

Profile summary based on public USPTO records.